TP53 mutation was an independent poor prognostic factor and the 3‐year RFS of MDS/AML patients with TP53 mutations was as low as 0%–7% even if they received allo‐HSCT.10, 17, 42. Here, TP53 is linked to myelodysplastic syndrome.